Yitai Pharmaceutical Co., Ltd. completed the pilot test of synthesis technology of related intermediates of radcivir API

Novel coronavirus (2019-nCoV) epidemic was launched in Hubei, Yitai pharmaceutical Limited by Share Ltd announced in February 17th Its pilot project has been completed successfully in the recent synthesis of the intermediate technology of Reed Wei Wei raw materials Novel coronavirus Reed novel coronavirus, developed by Gilead, USA, has been used in phase I and phase II clinical trials to prevent Ebola virus infection Currently, phase III clinical trials of Reed's new coronavirus (2019-nCoV) infection have not ended, so there is a great uncertainty about whether the new type of coronavirus (2019-nCoV) infection is effective The novel coronavirus (2019-nCoV) has been causing acute, infectious and high mortality The number of confirmed patients is long, and the latent period is long There is no effective clinical treatment It has already had a great impact on the economy and the lives of the masses Finding targeted antiviral drugs is imminent The novel coronavirus may be effective from the current trend of domestic media coverage, and its dosage is lower than that of Leigh Bhave Lin, and its side effects are also small Yitai Pharmaceutical Co., Ltd has completed the development of the small-scale test process of radcivir API intermediates since the end of 2018, and has completed the scale-up of kg level Mother nuclear process in the pilot test At that time, the project was not treated as a main variety, but as a downstream product of ribavirin, another antiviral product of our company, for their parent nuclear structure is consistent with the development strategy of antiviral API products formulated by the company Recently, Hubei Yitai Pharmaceutical Co., Ltd has completed the pilot test of intermediate of radcivir API, which can provide kilogram samples Hubei Yitai Pharmaceutical Co., Ltd will continue to pay attention to the results of phase III clinical trials of radcivir, and carry out follow-up work in time according to the needs of the country and society Hubei Yitai Pharmaceutical Co., Ltd Yitai Pharmaceutical Co., Ltd is a professional antiviral API manufacturer in China It has been focusing on the R & D and production of antiviral APIs for more than 20 years The novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) is one of the core products of the company, Leigh Bhave Lin Yitai pharmaceutical is the core supplier of ribavirin API, with a monthly production capacity of 15 tons, ranking the top three in China Yitai pharmaceutical novel coronavirus is currently in full supply with sufficient supply of raw materials, and it is officially resumed in February 12th of 20 to produce Leigh Bhave Lin raw material, which is expected to be fully loaded and put into battle against new coronavirus pneumonia, so as to ensure the supply of first-line drugs in urgent need 37